Latigo Biotherapeutics, Inc.
Latigo Biotherapeutics completed its initial public offering on August 10, 2026, generating $345.6 million in gross proceeds through the issuance of equity securities.
View raw filing on EDGAR →Filings Radar
SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Septerna, Inc. (SEPN)
Septerna disclosed its Q2 2026 financial results on August 10, 2026, including revenue of $26.7 million, R&D expenses of $35.1 million, net loss of $13.0 million, and cash position of $516.5 million. The filing includes a press release (Exhibit 99.1) announcing quarterly financial results and business highlights, which is the hallmark of an earnings release under Item 2.02.
View raw filing on EDGAR →LENSAR, Inc. (LNSR)
This is a clear disclosure of shareholder voting results from LENSAR's August 4, 2026 annual meeting of stockholders, filed under Item 5.07. The filing reports results for four proposals: election of three Class III directors (Thomas B. Ellis, Richard L. Lindstrom, MD, and William J. Link, PhD), ratification of PricewaterhouseCoopers LLP as auditor, advisory approval of named executive officer compensation, and advisory vote on compensation vote frequency (approved at one-year intervals). All proposals passed. This is a material governance event affecting investor understanding of board composition and corporate oversight.
View raw filing on EDGAR →GAIA, INC (GAIA)
This is a clear earnings release for Q2 2026 (quarter ended June 30, 2026) issued on August 10, 2026. The Item 2.02 disclosure explicitly states "Gaia, Inc. (the 'Company') issued a press release announcing results for its quarter ended June 30, 2026," with the full press release attached as Exhibit 99.1. The exhibit contains detailed financial results including revenue ($23.3M vs $24.6M YoY), net loss ($3.0M vs $1.8M YoY), and cash flow metrics, along with management commentary and condensed consolidated financial statements.
View raw filing on EDGAR →Olema Pharmaceuticals, Inc. (OLMA)
This is a standard quarterly earnings release for Q2 2026 filed under Item 2.02. The press release (Exhibit 99.1) discloses financial results including net loss of $63.2 million, R&D and G&A expenses, cash position of $461.1 million, and operating metrics. The filing also reports material clinical progress (OPERA-01 enrollment completion, OP-3136 Phase 1 data, Bayer collaboration), which are typical components of a biopharmaceutical company's earnings disclosure.
View raw filing on EDGAR →Vera Therapeutics, Inc. (VERA)
This is a press release announcing Vera Therapeutics' second quarter 2026 financial results, including net loss of $109.5 million and net loss per share of $1.52, along with cash position and operating cash flow metrics. The disclosure is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases. The material business updates regarding TRUTAKNA's FDA accelerated approval and commercial launch are presented alongside the financial results, making this a comprehensive earnings announcement.
View raw filing on EDGAR →ENANTA PHARMACEUTICALS INC (ENTA)
This is a clear earnings release for Enanta Pharmaceuticals' fiscal third quarter ended June 30, 2026. The Item 2.02 disclosure explicitly states "Enanta Pharmaceuticals, Inc. announced via press release its results for the fiscal quarter ended June 30, 2026," with the full press release furnished as Exhibit 99.1. The exhibit contains detailed financial results including revenue ($14.4 million), operating expenses, net loss ($19.5 million), and cash position ($211.5 million), along with operational updates on clinical programs. This is a standard quarterly earnings announcement material to investors.
View raw filing on EDGAR →FRACTYL HEALTH, INC. (GUTS)
This is a clear earnings release disclosing Fractyl Health's second quarter 2026 financial results, including R&D expenses ($13.8M), SG&A expenses ($5.3M), net loss ($25.5M), adjusted EBITDA (negative $16.3M), and cash position ($47.1M). The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings announcements. The disclosure includes both financial metrics and material clinical/business updates regarding the company's Revita and Rejuva programs.
View raw filing on EDGAR →ENTRAVISION COMMUNICATIONS CORP (EVC)
This is a clear earnings release disclosing Entravision's financial results for Q2 2026 and the six-month period ended June 30, 2026. The press release, furnished as Exhibit 99.1, reports consolidated net revenue of $227.9 million (up 126% YoY), segment operating profit of $36.7 million, and net income of $19.7 million for Q2 2026, along with detailed segment performance metrics and balance sheet information. The disclosure is material as it provides comprehensive quarterly financial results affecting investor assessment of the company's operational and financial performance.
View raw filing on EDGAR →Beachbody Company, Inc. (BODYW)
The filing discloses Beachbody's financial results for Q2 2026 (quarter ended June 30, 2026) via a press release attached as Exhibit 99.1. The disclosure includes detailed revenue ($49.6M), operating income ($1.7M), net income ($1.4M), and Adjusted EBITDA ($6.7M) figures, along with operational metrics and forward guidance for Q3 2026. This is a standard quarterly earnings announcement material to investors assessing the company's financial performance and trajectory.
View raw filing on EDGAR →PUBLIC SERVICE CO OF COLORADO
PSCo issued $800 million in aggregate principal amount of First Mortgage Bonds in two series ($150 million 2034 Bonds at 5.35% and $650 million 2056 Bonds at 6.20%), creating new direct financial obligations. The disclosure explicitly describes the issuance date, principal amounts, interest rates, maturity dates, underwriters, and governing indentures—all hallmarks of a material debt issuance under Item 2.03 (though filed under Item 8.01). This is a substantial capital-raising transaction material to investors.
View raw filing on EDGAR →American Healthcare REIT, Inc. (AHR)
American Healthcare REIT entered into three purchase agreements on August 10, 2026 to acquire eight senior housing communities (the "Kensington Portfolio") for an aggregate purchase price of $873 million. This constitutes a material acquisition of real property and operating business assets, with closing conditions and timelines extending through 2026. The transaction is explicitly disclosed under Item 1.01 (Entry into a Material Definitive Agreement) and represents a significant capital deployment that would materially affect investor assessment of the registrant's financial position and strategy.
View raw filing on EDGAR →ADTRAN Holdings, Inc. (ADTN)
The disclosure centers on an amendment to Dr. Christoph Glingener's employment agreement as CTO, detailing modifications to his compensatory arrangements including base salary affirmation (€400,000), annual incentive cash bonus targets (60% of base), time-based RSU grants (75% of base, capped at €903,729), and three-year performance stock unit awards (€903,729 target, capped at €2,000,000). The Amendment also establishes a total annual remuneration cap of €2,800,000. This is a classic executive compensation disclosure under Item 5.02(e), distinct from a departure or appointment.
View raw filing on EDGAR →TERADYNE, INC (TER)
Teradyne entered into a Credit Agreement on August 7, 2026, establishing a $1.0 billion five-year senior secured revolving credit facility with PNC Bank as administrative agent. The facility includes detailed covenants, financial ratios, collateral, and guarantees, representing a material creation of a new direct financial obligation.
View raw filing on EDGAR →Shimmick Corp (SHIM)
Shimmick Corporation issued a press release on August 10, 2026 announcing financial results for Q2 2026 ended July 3, 2026, disclosing revenue of $107 million, gross margin of $12 million, net loss of $5 million, and Adjusted EBITDA of $4 million. The filing explicitly states this is an earnings release furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for quarterly earnings disclosures. The release includes detailed financial tables, segment performance analysis, and updated full-year 2026 guidance, all hallmarks of a quarterly earnings announcement.
View raw filing on EDGAR →Sana Biotechnology, Inc. (SANA)
This is a clear earnings release disclosing Sana Biotechnology's financial results for Q2 2026 (quarter ended June 30, 2026), filed under Item 2.02 Results of Operations and Financial Condition. The press release (Exhibit 99.1) reports GAAP and non-GAAP financial metrics including cash position ($160.5M), R&D expenses ($30.7M for Q2), net loss ($63.6M for Q2), and operating cash burn, along with business highlights on clinical program progress. This is a standard quarterly earnings disclosure material to investors assessing the company's financial condition and operational progress.
View raw filing on EDGAR →GEN Restaurant Group, Inc. (GENK)
GEN Restaurant Group issued a press release on August 10, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing Q2 2026 revenue of $55.7 million, net loss of $(4.6) million, and other key financial metrics. This is a standard quarterly earnings release furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is material to investors assessing the company's financial performance and operational trends.
View raw filing on EDGAR →Alamar Biosciences, Inc. (ALMR)
This is a straightforward earnings release for Q2 2026 financial results. The 8-K Item 2.02 discloses quarterly revenue of $29.4 million (82% YoY growth), gross margin of 60%, operating loss of $13.5 million, and net loss of $13.2 million, along with full-year 2026 revenue guidance of $116–$120 million. The press release is attached as Exhibit 99.1 and includes detailed financial statements and operational highlights. This is material to investors assessing the registrant's financial performance and trajectory.
View raw filing on EDGAR →Greystone Housing Impact Investors LP (GHI)
Greystone Housing Impact Investors LP disclosed its financial results for the second quarter ended June 30, 2026, including a net loss of $1.52 million per BUC, Cash Available for Distribution of $0.10 per BUC, and total assets of $1.39 billion, with condensed consolidated statements of operations comparing Q2 2026 to Q2 2025 and six-month periods.
View raw filing on EDGAR →Definitive Healthcare Corp. (DH)
This is a clear earnings release disclosing Definitive Healthcare's Q2 2026 financial results for the quarter ended June 30, 2026. The press release, furnished as Exhibit 99.1, presents key financial metrics including revenue ($55.2M), net loss, adjusted net income, adjusted EBITDA, and cash flow, along with forward guidance for Q3 and full-year 2026. The Item 2.02 disclosure and attached press release are the hallmark of an earnings announcement, which is material to investors assessing the company's operational and financial performance.
View raw filing on EDGAR →Metagenomi Therapeutics, Inc. (MGX)
This is a standard quarterly earnings release for Q2 2026 filed under Item 2.02. The disclosure includes condensed financial statements (balance sheet and statements of operations), cash position ($120.7 million), R&D and G&A expenses, net loss per share ($0.73), and business updates regarding the MGX-001 hemophilia A program. The press release is furnished as Exhibit 99.1 and contains both financial results and operational milestones typical of an earnings announcement.
View raw filing on EDGAR →Alphabet Inc. (GOOG)
Alphabet closed an underwritten public offering of $25 billion in U.S. dollar-denominated senior notes across multiple tranches with varying maturity dates (2028–2066) and interest rates. This is a material creation of direct financial obligations disclosed under Item 8.01, constituting a debt issuance event.
View raw filing on EDGAR →PROKIDNEY CORP. (PROK)
ProKidney issued a press release on August 10, 2026, announcing financial results for the quarter ended June 30, 2026, with consolidated balance sheets, statements of operations, and cash flow statements attached as Exhibit 99.1. The disclosure includes Q2 2026 financial highlights (cash position of $181.6 million, R&D expenses of $36.1 million, net loss of $46.4 million) and material business milestones (completion of accelerated approval efficacy analysis enrollment, appointment of Chief Technical Officer). This is a standard quarterly earnings release disclosure under Item 2.02.
View raw filing on EDGAR →Nkarta, Inc. (NKTX)
This is a straightforward earnings release for Q2 2026 ended June 30, 2026. The Item 2.02 disclosure announces financial results via a press release (Exhibit 99.1) that includes condensed statements of operations and balance sheets, net loss of $40.4 million ($0.54 per share), R&D and G&A expenses, cash position of $243.2 million, and financial guidance extending cash runway into 2029. The filing explicitly states "Nkarta, Inc. (the 'Company') will issue a press release announcing its financial results for the second quarter ended June 30, 2026."
View raw filing on EDGAR →Crescent Capital BDC, Inc. (FCRX)
This is a clear earnings release disclosing quarterly financial results for the period ended June 30, 2026. The press release reports net investment income of $0.36 per share, net income of $(0.09) per share, NAV per share of $17.82, and includes detailed financial statements and portfolio information. The Item 2.02 disclosure and attached Exhibit 99.1 are standard for quarterly earnings announcements by BDCs.
View raw filing on EDGAR →Repay Holdings Corp (RPAY)
Repay Holdings Corporation issued a press release on August 10, 2026 announcing Q2 2026 financial results for the quarter ended June 30, 2026, reporting revenue of $100.7 million (33% growth), Adjusted EBITDA of $36.3 million, and Free Cash Flow of $27.4 million, along with full-year 2026 guidance.
View raw filing on EDGAR →Celsius Holdings, Inc. (CELH)
Eric Hanson, President and Chief Operating Officer of Celsius Holdings, departed effective August 10, 2026, as part of an organizational realignment. The departure is accompanied by severance benefits eligibility and concurrent appointments of Tyler Bohannon as Chief Commercial Officer and Tony Guilfoyle as Chief Business Transformation Officer.
View raw filing on EDGAR →SURF AIR MOBILITY INC. (SRFM)
This is a clear earnings release disclosing Surf Air Mobility's Q2 2026 financial results. The filing explicitly states "On August 10, 2026, Surf Air Mobility Inc. issued a press release announcing the Company's financial results for the quarter ended June 30, 2026," with the press release furnished as Exhibit 99.1. The exhibit contains detailed quarterly revenue ($29.5 million), net loss ($28.1 million), Adjusted EBITDA loss ($10.5 million), and forward guidance for Q3 and full-year 2026, all hallmarks of an earnings release.
View raw filing on EDGAR →PUBLIC SERVICE ELECTRIC & GAS CO
PSE&G completed a public offering of $1 billion in aggregate principal amount of secured medium-term notes ($650 million due 2036 and $350 million due 2056). This is a material creation of direct financial obligations disclosed under Item 8.01, constituting a debt issuance event.
View raw filing on EDGAR →Ceribell, Inc. (CBLL)
Ceribell issued a press release on August 10, 2026 announcing financial results for the fiscal quarter ended June 30, 2026. The disclosure includes detailed quarterly revenue ($28.1 million, up 33% YoY), gross margin (92%), net loss ($19.3 million), and updated full-year 2026 revenue guidance ($114–$117 million). This is a standard earnings release filed under Item 2.02 with financial statements and forward-looking guidance, materially affecting investor assessment of the company's financial performance and trajectory.
View raw filing on EDGAR →Private Bancorp of America, Inc.
The disclosure centers on a compensatory arrangement for Richard L. Sowers, the President and CEO, specifically the grant of a stock option for 30,000 shares under the 2026 Omnibus Equity Incentive Plan with an exercise price of $85.65 and performance-based vesting tied to 2028 audited financial statements. This is a classic executive compensation event under Item 5.02(e), distinct from an appointment or departure.
View raw filing on EDGAR →Perspective Therapeutics, Inc. (CATX)
Perspective Therapeutics disclosed Q2 2026 financial results for the quarter ended June 30, 2026, reporting a net loss of $26.8 million ($0.22 per share), R&D expenses of $21.5 million, G&A expenses of $7.8 million, and a cash position of $237 million. The disclosure includes condensed consolidated financial statements and business highlights with clinical program updates.
View raw filing on EDGAR →MASTEC INC (MTZ)
MasTec entered into an Underwriting Agreement on August 6, 2026 to issue $650 million of 5.850% Senior Notes due 2036, with pricing announced and expected closing on August 17, 2026. The company intends to use net proceeds to repay its $600 million term loan and for general corporate purposes.
View raw filing on EDGAR →Annexon, Inc. (ANNX)
Annexon appointed Mark S. Blumenkranz, M.D., M.M.S. to its board of directors effective August 10, 2026, and assigned him to the Audit Committee and Science and Technology Committee. Dr. Blumenkranz brings significant expertise in retinal disease and biotechnology leadership to support the company's late-stage clinical programs.
View raw filing on EDGAR →Public Storage (PSA-PS)
The filing discloses the appointment of S. Wade Sheek as Chief Legal Officer and Corporate Secretary, effective August 17, 2026, replacing Nathaniel A. Vitan. While the section also mentions Vitan's transition to a senior advisor role, the principal disclosed action is the appointment of a named executive officer to a C-suite position. This is material as it affects the registrant's senior leadership and governance structure.
View raw filing on EDGAR →KLX Energy Services Holdings, Inc. (KLXE)
KLX Energy Services announced a $125 million backstopped rights offering on August 6, 2026, with each right entitling shareholders to purchase 3.885 shares at $1.49 per share. The backstop commitment of $94 million will be satisfied through a debt-for-equity exchange with holders of the company's 2030 Notes, with unregistered shares issued in reliance on Section 4(a)(2) of the Securities Act, representing a material dilutive capital raise designed to reduce leverage.
View raw filing on EDGAR →AST SpaceMobile, Inc. (ASTS)
AST SpaceMobile issued a press release on August 10, 2026 announcing Q2 2026 financial results, disclosing revenue of $31.5 million, operating expenses of $329.1 million, and a cash position of approximately $2.7 billion as of June 30, 2026, along with full-year 2026 revenue guidance of $150.0–$200.0 million.
View raw filing on EDGAR →Innovex International, Inc. (INVX)
The filing discloses an underwriting agreement for a secondary offering of 5,000,000 shares of common stock by selling stockholders (Amberjack Capital Partners affiliates) at $28.71 per share, closed on August 10, 2026. While the Company itself did not issue new shares or receive proceeds, the secondary offering represents a substantial dilutive event affecting existing shareholders' ownership percentages. This is material to investors assessing capital structure and ownership dilution, though the dilutive impact is less direct than a primary offering where the Company itself issues shares.
View raw filing on EDGAR →Archer-Daniels-Midland Co (ADM)
ADM issued $500 million of 4.829% Notes due 2031 and $500 million of 5.269% Notes due 2036 on August 10, 2026, totaling $1 billion in new debt. The filing explicitly states the notes were issued and includes the underwriting agreement and note forms as exhibits, clearly indicating creation of a new direct financial obligation under Item 9.01.
View raw filing on EDGAR →Bain Capital Specialty Finance, Inc. (BCSF)
Bain Capital Specialty Finance disclosed Q2 2026 financial results ended June 30, 2026, reporting net investment income per share of $0.44, net income per share of $0.22, and net asset value per share of $16.65, with consolidated financial statements included.
View raw filing on EDGAR →Bain Capital Specialty Finance, Inc. (BCSF)
The company declared a third fiscal quarter 2026 dividend of $0.42 per share, payable to stockholders of record as of September 15, 2026, with payment on September 29, 2026.
View raw filing on EDGAR →HELIOS TECHNOLOGIES, INC. (HLIO)
This is a clear earnings release for Q2 2026 (ended July 4, 2026) filed under Item 2.02. The press release discloses comprehensive financial results including net sales of $231.9 million (up 9% YoY), diluted EPS of $0.66 (up 94%), adjusted diluted EPS of $0.88 (up 49%), and raised full-year 2026 outlook. The company also highlights operational achievements including record operating cash flow, margin expansion, and capital returns to shareholders.
View raw filing on EDGAR →Broadstone Net Lease, Inc. (BNL)
Broadstone Net Lease completed a public offering of 11,000,000 shares of common stock at $20.50 per share, with an additional 1,650,000 shares from the full exercise of the underwriters' option, totaling 12,650,000 shares. The company also entered into forward sale agreements with forward purchasers, creating a dilutive equity issuance structure. This is a material capital-raising event that increases share count and dilutes existing shareholders.
View raw filing on EDGAR →Capital Clean Energy Carriers Corp. (CCEC)
The 6-K announces the nomination of Ms. Janet DiFiore to the Board of Directors to fill the seat vacated by Mr. Gurpal Grewal, who determined not to stand for re-election. Although the appointment is subject to shareholder approval at the upcoming annual meeting, the principal disclosed action is the nomination of a director candidate with substantial public-sector credentials (former Chief Judge of New York Court of Appeals). This is a material governance event affecting board composition.
View raw filing on EDGAR →Flowco Holdings Inc. (FLOC)
The filing discloses a declaration by Flowco's Board of Directors of a one-time special cash dividend of $0.14 per share of Class A common stock, payable August 31, 2026. This is a direct and unambiguous dividend distribution event. While characterized as non-recurring and discretionary, the declaration and payment terms constitute a material capital allocation decision affecting shareholders.
View raw filing on EDGAR →FiscalNote Holdings, Inc. (NOTEW)
FiscalNote disclosed Q2 2026 financial results on August 10, 2026, via press release furnished as Exhibit 99.1. The filing reports total revenues of $19.6 million (in line with guidance), adjusted EBITDA of $2.3 million (slightly below guidance), and includes a material $19.1 million goodwill impairment charge. The company also revised full-year 2026 guidance downward from $80–$83M to $75–$78M in revenues and from $14–$16M to $9–$11M in adjusted EBITDA, reflecting softness in federal and public sector spending. This is a standard quarterly earnings release with material guidance revisions and impairment charges.
View raw filing on EDGAR →GEN Restaurant Group, Inc. (GENK)
GEN Restaurant Group entered into an at-the-market (ATM) sales agreement with Roth Capital Partners to offer up to $3.74 million in Class A common stock. This is a dilutive equity issuance under Rule 415, structured as an ATM offering. The company explicitly states it "may offer and sell shares" and is "not obligated to sell any Shares," but the agreement itself represents a material capital-raising mechanism that would dilute existing shareholders and is disclosed under Item 1.01 (Material Definitive Agreement).
View raw filing on EDGAR →Jazz Pharmaceuticals plc (JAZZ)
Jazz Pharmaceuticals entered into an Agreement and Plan of Merger on August 10, 2026, to acquire Actio Biosciences, Inc. for an upfront transaction value of $820 million plus contingent milestone payments up to $500 million. This is a material acquisition disclosed under Item 1.01 (Entry into a Material Definitive Agreement), representing a significant M&A transaction that would materially affect investor assessment of the registrant.
View raw filing on EDGAR →Erasca, Inc. (ERAS)
Dr. Charles S. Fuchs was appointed President, Research & Development of Erasca, Inc., effective August 10, 2026. This is a material executive appointment of a senior officer with significant oncology and biopharmaceutical development experience, including prior roles at Roche/Genentech and Yale Cancer Center. The appointment includes substantial compensation (base salary $570,000, 45% bonus target, and 1.3 million stock options), making it material to investors' assessment of the company's leadership and strategic direction.
View raw filing on EDGAR →SONIDA SENIOR LIVING, INC. (SNDA)
The Company entered into an Exchange Agreement dated August 10, 2026, involving a material restructuring of its capital structure through the issuance of 41,250 shares of Series B Convertible Preferred Stock and 1,601,505 shares of Common Stock in exchange for the surrender of previously issued shares, effectively resolving litigation over the validity of prior preferred stock conversions.
View raw filing on EDGAR →